WITHDRAWN: ROS/KRAS/AMPK Signaling Determines Gemcitabine-Induced Pancreatic Cancer Stem-Like Cell Property in Vitro
Hengqiang Zhao,Hehe Li,Qing Duan,Zhengle Zhang,Heshui Wu,Qiang Shen,Chunyou Wang,Tao Yin
DOI: https://doi.org/10.18632/oncotarget.24081
2018-01-01
Oncotarget
Abstract:// Hengqiang Zhao 1 , Hehe Li 1 , Qingke Duan 1 , Zhengle Zhang 1 , Heshui Wu 1 , Qiang Shen 2 , Chunyou Wang 1 and Tao Yin 1 1 Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China 2 Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Correspondence to: Tao Yin, email: ytwhun@126.com Chunyou Wang, email: chunyouwang52@126.com Keywords: ROS; KRAS; AMPK; glycolysis; cancer stem cells Received: June 20, 2017 Accepted: January 04, 2018 Published: January 09, 2018 ABSTRACT Poor prognosis of pancreatic cancer (PanCa) is partially due to chemoresistance to gemcitabine (GEM), the standard chemotherapy. Dysregulated glucose metabolism is revealed to contribute to therapeutic resistance and pluripotent state. Cancer stem cells (CSCs) rewire cellular metabolism to survive the chemotherapeutics and initiate cancer relapse. However, few studies focus on the effect of GEM on cancer cell metabolism, the stemness status, and the involved mechanisms which are crucial in PanCa treatment. In this study, we demonstrate that GEM treatment induces metabolic reprogramming from mitochondrial oxidation to glycolysis and promotes cancer stem-like status. However, inhibition of glycolysis using 2-deoxy-D-glucose (2-DG) suppresses cancer stemness and strengthens the cytotoxicity of GEM. We further demonstrate that GEM-induced metabolic reprogramming is KRAS -dependent as knockdown of KRAS reverses the metabolic shift. In addition, GEM-induced metabolic reprogramming activates AMP-activated protein kinase (AMPK) which promotes glycolytic flux and cancer stemness. Our results further reveal the involvement of GEM-induced reactive oxygen species (ROS) in the activation of KRAS/AMPK pathway in regulation of metabolic reprogramming and cancer stemness, while N-acetyl-L-cysteine (NAC), a ROS scavenger, inhibits the activated KRAS/AMPK pathway, which is further validated by introducing exogenous hydrogen peroxide (H 2 O 2 ). Collectively, these findings reveal an undesired effect of GEM in PanCa treatment. Therefore, regulating cellular redox, targeting KRAS/AMPK signaling, or reversing metabolic reprogramming may be effective approaches to eliminate CSCs and enhance chemosensitivity of GEM to improve the prognosis of patients with PanCa.